# To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer

> **NCT04671303** · PHASE2 · COMPLETED · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 36 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Anlotinib Hydrochloride Capsule Combined with Furmonertinib Mesylate

## Key facts

- **NCT ID:** NCT04671303
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-01
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-07-27
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04671303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04671303, "To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04671303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*